These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39084437)

  • 1. Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs).
    Abbas A; Ye F
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134293. PubMed ID: 39084437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROTACable Is an Integrative Computational Pipeline of 3-D Modeling and Deep Learning To Automate the De Novo Design of PROTACs.
    Mslati H; Gentile F; Pandey M; Ban F; Cherkasov A
    J Chem Inf Model; 2024 Apr; 64(8):3034-3046. PubMed ID: 38504115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras.
    Li F; Hu Q; Zhou Y; Yang H; Bai F
    Brief Bioinform; 2024 Jul; 25(5):. PubMed ID: 39101502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benchmarking Methods for PROTAC Ternary Complex Structure Prediction.
    Rovers E; Schapira M
    J Chem Inf Model; 2024 Aug; 64(15):6162-6173. PubMed ID: 39087481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
    Liu Z; Liu S
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of Three-Body Problems and Protein-Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations.
    Li W; Zhang J; Guo L; Wang Q
    J Chem Inf Model; 2022 Feb; 62(3):523-532. PubMed ID: 35084845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nano-PROTACs: state of the art and perspectives.
    Zhong J; Zhao R; Wang Y; Su YX; Lan X
    Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development.
    Danishuddin ; Jamal MS; Song KS; Lee KW; Kim JJ; Park YM
    Pharmaceuticals (Basel); 2023 Nov; 16(12):. PubMed ID: 38139776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Modeling of PROTAC-Mediated Ternary Complexes.
    Weng G; Li D; Kang Y; Hou T
    J Med Chem; 2021 Nov; 64(21):16271-16281. PubMed ID: 34709816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTAC-Design-Evaluator (PRODE): An Advanced Method for In-Silico PROTAC Design.
    A S BG; Agrawal D; Kulkarni NM; Vetrivel R; Gurram K
    ACS Omega; 2024 Mar; 9(11):12611-12621. PubMed ID: 38524483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallization of VHL-based PROTAC-induced ternary complexes.
    Wijaya AJ; Farnaby W; Ciulli A
    Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes.
    Zaidman D; Prilusky J; London N
    J Chem Inf Model; 2020 Oct; 60(10):4894-4903. PubMed ID: 32976709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs).
    Saraswat AL; Vartak R; Hegazy R; Patel A; Patel K
    Drug Discov Today; 2023 Jan; 28(1):103387. PubMed ID: 36184017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras.
    Bhole RP; Patil S; Kapare HS; Chikhale RV; Gurav SS
    Curr Top Med Chem; 2024; 24(23):2050-2073. PubMed ID: 38963108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifunctional robots inducing targeted protein degradation.
    Sobhia ME; Kumar H; Kumari S
    Eur J Med Chem; 2023 Jul; 255():115384. PubMed ID: 37119667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.